RE: Timing of results23 Jun 2020 10:21
Inhaled medications are the backbone of care for COPD today.
They are the next generation of inhaled medicines, addressing unmet needs in exacerbation control and following the science behind all-cause mortality to better understand how to prevent early death from this devastating progressive disease.
The chronic obstructive pulmonary disease (COPD) space across the eight major markets of the US, France, Germany, Italy, Spain, the UK, Japan, and Australia, is set to rise from $9.9 billion in 2015 to around $14.1 billion by 2025.
Plenty of demand.